Which has stronger earnings & valuation, IVA or OGN?

Organon & Co. has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 198.29 -$400.67M N/A N/A Organon & Co. $6.22B 0.58 $187M $0.77 17.90

Does the media prefer IVA or OGN?

In the previous week, Inventiva had 2 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Inventiva and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.51 beat Inventiva's score of 0.13 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GPCR or IVA?

Structure Therapeutics has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A Inventiva $5.07M 198.29 -$400.67M N/A N/A

Is GPCR or IVA more profitable?

Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -25.56% -24.31% Inventiva N/A N/A N/A

Does the media favor GPCR or IVA?

In the previous week, Inventiva had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Inventiva and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.94 beat Inventiva's score of 0.13 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, IVA or MBX?

MBX Biosciences has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 198.29 -$400.67M N/A N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is IVA or MBX more profitable?

Inventiva's return on equity of 0.00% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A MBX Biosciences N/A -26.02% -24.94%

Does the media prefer IVA or MBX?

In the previous week, Inventiva had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Inventiva and 6 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.28 beat Inventiva's score of 0.13 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TARS or IVA?

Tarsus Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tarsus Pharmaceuticals $451.36M 8.09 -$66.42M -$1.09 N/A Inventiva $5.07M 198.29 -$400.67M N/A N/A

Does the media refer more to TARS or IVA?

In the previous week, Tarsus Pharmaceuticals had 6 more articles in the media than Inventiva. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 8 mentions for Inventiva. Tarsus Pharmaceuticals' average media sentiment score of 1.34 beat Inventiva's score of 0.13 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IVA or ARQT?

Arcutis Biotherapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 198.29 -$400.67M N/A N/A Arcutis Biotherapeutics $376.07M 7.91 -$16.14M $0.21 112.67

Does the media favor IVA or ARQT?

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 8 mentions for Inventiva. Arcutis Biotherapeutics' average media sentiment score of 1.11 beat Inventiva's score of 0.13 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inventiva (IVA) Competitors

$4.84 -0.02 (-0.41%)

As of 04:00 PM Eastern

Compare

IVA vs. OGN, GPCR, MBX, TARS, and ARQT

Should you buy Inventiva stock or one of its competitors? Inventiva's main competitors and comparable companies include Organon & Co. (OGN), Structure Therapeutics (GPCR), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inventiva compare to Organon & Co.?

Inventiva (NASDAQ:IVA) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Inventiva had 2 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Inventiva and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.51 beat Inventiva's score of 0.13 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.1% of Inventiva shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to Inventiva's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Organon & Co.	3.41%	88.97%	6.03%

Inventiva currently has a consensus price target of $15.38, indicating a potential upside of 217.67%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 17.27%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Inventiva has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.90

Summary

Organon & Co. beats Inventiva on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Structure Therapeutics currently has a consensus target price of $110.91, suggesting a potential upside of 134.28%. Inventiva has a consensus target price of $15.38, suggesting a potential upside of 217.67%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Structure Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A

Structure Therapeutics has a beta of -1.45, suggesting that its share price is 245% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

In the previous week, Inventiva had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Inventiva and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.94 beat Inventiva's score of 0.13 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Inventiva	N/A	N/A	N/A

Summary

Inventiva beats Structure Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Inventiva compare to MBX Biosciences?

Inventiva (NASDAQ:IVA) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Inventiva had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Inventiva and 6 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.28 beat Inventiva's score of 0.13 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva presently has a consensus price target of $15.38, indicating a potential upside of 217.67%. MBX Biosciences has a consensus price target of $77.00, indicating a potential upside of 25.37%. Given Inventiva's stronger consensus rating and higher probable upside, equities analysts clearly believe Inventiva is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Inventiva has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Inventiva's return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
MBX Biosciences	N/A	-26.02%	-24.94%

19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MBX Biosciences has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Summary

Inventiva beats MBX Biosciences on 10 of the 13 factors compared between the two stocks.

How does Inventiva compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Tarsus Pharmaceuticals had 6 more articles in the media than Inventiva. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 8 mentions for Inventiva. Tarsus Pharmaceuticals' average media sentiment score of 1.34 beat Inventiva's score of 0.13 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

Inventiva has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Inventiva's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Inventiva	N/A	N/A	N/A

Tarsus Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	8.09	-$66.42M	-$1.09	N/A
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A

Tarsus Pharmaceuticals currently has a consensus target price of $90.50, indicating a potential upside of 8.76%. Inventiva has a consensus target price of $15.38, indicating a potential upside of 217.67%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Summary

Inventiva beats Tarsus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Inventiva compare to Arcutis Biotherapeutics?

Inventiva (NASDAQ:IVA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Inventiva has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 8 mentions for Inventiva. Arcutis Biotherapeutics' average media sentiment score of 1.11 beat Inventiva's score of 0.13 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A
Arcutis Biotherapeutics	$376.07M	7.91	-$16.14M	$0.21	112.67

Arcutis Biotherapeutics has a net margin of 6.15% compared to Inventiva's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Inventiva currently has a consensus target price of $15.38, suggesting a potential upside of 217.67%. Arcutis Biotherapeutics has a consensus target price of $35.57, suggesting a potential upside of 50.34%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Arcutis Biotherapeutics beats Inventiva on 8 of the 14 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	N/A	787.27	273.28	25.38
Price / Sales	198.29	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-22.00	12.33	12.89	6.14
Net Income	-$400.67M	$2.82B	$3.47B	$349.01M
7 Day Performance	-1.22%	1.97%	-0.33%	-1.47%
1 Month Performance	13.88%	4.87%	6.51%	2.47%
1 Year Performance	-16.12%	9.15%	25.19%	15.84%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	2.3159 of 5 stars	$4.84 -0.4%	$15.38 +217.7%	-7.6%	$1.01B	$5.07M	N/A	100	News Coverage
OGN Organon & Co.	1.7514 of 5 stars	$13.76 +0.0%	$11.40 -17.1%	+46.5%	$3.61B	$6.22B	17.85	10,000
GPCR Structure Therapeutics	2.3117 of 5 stars	$49.68 +1.4%	$110.91 +123.2%	+138.0%	$3.46B	N/A	N/A	136	Positive News
MBX MBX Biosciences	2.7616 of 5 stars	$68.66 +3.4%	$77.00 +12.2%	+317.9%	$3.31B	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	2.3969 of 5 stars	$71.95 -1.2%	$90.50 +25.8%	+41.3%	$3.16B	$451.36M	N/A	50	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. OGN, GPCR, MBX, TARS, and ARQT

How does Inventiva compare to Organon & Co.?

Summary

How does Inventiva compare to Structure Therapeutics?

Summary

How does Inventiva compare to MBX Biosciences?

Summary

How does Inventiva compare to Tarsus Pharmaceuticals?

Summary

How does Inventiva compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. OGN, GPCR, MBX, TARS, and ARQT

How does Inventiva compare to Organon & Co.?

Does the media prefer IVA or OGN?

Do insiders & institutionals have more ownership in IVA or OGN?

Is IVA or OGN more profitable?

Do analysts prefer IVA or OGN?

Which has more risk and volatility, IVA or OGN?

Which has stronger earnings & valuation, IVA or OGN?

Summary

How does Inventiva compare to Structure Therapeutics?

Do analysts prefer GPCR or IVA?

Which has preferable earnings and valuation, GPCR or IVA?

Which has more volatility and risk, GPCR or IVA?

Does the media favor GPCR or IVA?

Do insiders and institutionals have more ownership in GPCR or IVA?

Is GPCR or IVA more profitable?

Summary

How does Inventiva compare to MBX Biosciences?

Does the media prefer IVA or MBX?

Do analysts recommend IVA or MBX?

Which has more volatility and risk, IVA or MBX?

Is IVA or MBX more profitable?

Do insiders & institutionals believe in IVA or MBX?

Which has better earnings & valuation, IVA or MBX?

Summary

How does Inventiva compare to Tarsus Pharmaceuticals?

Do institutionals and insiders believe in TARS or IVA?

Does the media refer more to TARS or IVA?

Which has more risk and volatility, TARS or IVA?

Is TARS or IVA more profitable?

Which has higher valuation and earnings, TARS or IVA?

Do analysts rate TARS or IVA?

Summary

How does Inventiva compare to Arcutis Biotherapeutics?

Which has more volatility and risk, IVA or ARQT?

Does the media favor IVA or ARQT?

Do insiders and institutionals hold more shares of IVA or ARQT?

Which has stronger earnings and valuation, IVA or ARQT?

Is IVA or ARQT more profitable?

Do analysts rate IVA or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools